P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

• J. J. Castillo,
• E. C. Kingsley,
• M. Narang,
• H. A. Yimer,
• C. A. Dasanu,
• J. M. Melear,
• M. Coleman,
• C. M. Farber,
• M. Gupta,
• J. Shulman,
• E. H. Mantovani,
• X. Zhang,
• A. Cohen,
• J. Huang

Affiliations

J. J. Castillo

1 Dana-Farber Cancer Institute, Boston, MA

E. C. Kingsley

2 Comprehensive Cancer Centers of Nevada, Las Vegas, NV

M. Narang

3 US Oncology Research, Maryland Hematology Oncology, Columbia, MD

H. A. Yimer

4 Texas Oncology, US Oncology Research, Tyler, TX

C. A. Dasanu

5 Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA

J. M. Melear

6 US Oncology Research, Texas Oncology, Austin Midtown, Austin, TX

M. Coleman

7 Clinical Research Alliance, New York, NY

C. M. Farber

8 Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ

M. Gupta

9 Ridley-Tree Cancer Center at Sansum Clinic, Santa Barbara, CA

J. Shulman

10 Icahn School of Medicine at Mount Sinai, New York, NY

E. H. Mantovani

11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

X. Zhang

11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

A. Cohen

11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

J. Huang

11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America